A novel BCMA PBD-ADC with ATM/ATR/WEE1 inhibitors or bortezomib induce synergistic lethality in multiple myeloma

Antibody–drug conjugate, GSK2857916, in relapsed/refractory multiple myeloma: an update on safety and efficacy from dose expansion phase I study

(2019) Suzanne Trudel et al.   Blood Cancer Journal

Antibody–Drug Conjugates: Future Directions in Clinical and Translational Strategies to Improve the Therapeutic Index

(2019) Steven Coats et al.   CLINICAL CANCER RESEARCH

B cell maturation antigen–specific CAR T cells are clinically active in multiple myeloma

(2019) Adam D. Cohen et al.   JOURNAL OF CLINICAL INVESTIGATION

Anti-BCMA CAR T-Cell Therapy bb2121 in Relapsed or Refractory Multiple Myeloma

(2019) Noopur Raje et al.   NEW ENGLAND JOURNAL OF MEDICINE

B cell maturation antigen (BCMA)-based immunotherapy for multiple myeloma

(2019) Yu-Tzu Tai et al.   EXPERT OPINION ON BIOLOGICAL THERAPY

ADCT-402, a PBD dimer–containing antibody drug conjugate targeting CD19-expressing malignancies

(2018) Francesca Zammarchi et al.   BLOOD

From MGUS to Multiple Myeloma, a Paradigm for Clonal Evolution of Premalignant Cells

(2018) Niels van Nieuwenhuijzen et al.   CANCER RESEARCH

A review discussing elotuzumab and its use in the second-line plus treatment of multiple myeloma

(2018) Massimo Offidani et al.   Future Oncology

T Cells Genetically Modified to Express an Anti–B-Cell Maturation Antigen Chimeric Antigen Receptor Cause Remissions of Poor-Prognosis Relapsed Multiple Myeloma

(2018) Jennifer N. Brudno et al.   JOURNAL OF CLINICAL ONCOLOGY

The Identification of Potent, Selective, and Orally Available Inhibitors of Ataxia Telangiectasia Mutated (ATM) Kinase: The Discovery of AZD0156 (8-{6-[3-(Dimethylamino)propoxy]pyridin-3-yl}-3-methyl-1-(tetrahydro-2H-pyran-4-yl)-1,3-dihydro-2H-imidazo[4,5-c]quinolin-2-one)

(2018) Kurt G. Pike et al.   JOURNAL OF MEDICINAL CHEMISTRY

Multiple myeloma clonal evolution in homogeneously treated patients

(2018) Jill Corre et al.   LEUKEMIA

EMA Review of Daratumumab for the Treatment of Adult Patients with Multiple Myeloma

(2018) Kyriaki Tzogani et al.   ONCOLOGIST

Promise of Immune Therapies in Multiple Myeloma

(2018) Kenneth C. Anderson   Journal of Oncology Practice

Strategic development of AZD1775, a Wee1 kinase inhibitor, for cancer therapy

(2018) Siqing Fu et al.   EXPERT OPINION ON INVESTIGATIONAL DRUGS

Targeting B Cell Maturation Antigen (BCMA) in Multiple Myeloma: Potential Uses of BCMA-Based Immunotherapy

(2018) Shih-Feng Cho et al.   Frontiers in Immunology

Introduction to the review series on advances in multiple myeloma

(2018) Hervé Avet-Loiseau   BLOOD

Discovery and Characterization of AZD6738, a Potent Inhibitor of Ataxia Telangiectasia Mutated and Rad3 Related (ATR) Kinase with Application as an Anticancer Agent

(2018) Kevin M. Foote et al.   JOURNAL OF MEDICINAL CHEMISTRY

Targeting B-cell maturation antigen with GSK2857916 antibody–drug conjugate in relapsed or refractory multiple myeloma (BMA117159): a dose escalation and expansion phase 1 trial

(2018) Suzanne Trudel et al.   LANCET ONCOLOGY

Preclinical assessment of an antibody–PBD conjugate that targets BCMA on multiple myeloma and myeloma progenitor cells

(2018) Krista Kinneer et al.   LEUKEMIA

Rovalpituzumab tesirine, a DLL3-targeted antibody-drug conjugate, in recurrent small-cell lung cancer: a first-in-human, first-in-class, open-label, phase 1 study

(2017) Charles M Rudin et al.   LANCET ONCOLOGY

Nucleotide excision repair is a potential therapeutic target in multiple myeloma

(2017) R Szalat et al.   LEUKEMIA

Efficient Preparation of Site-Specific Antibody–Drug Conjugates Using Cysteine Insertion

(2017) Nazzareno Dimasi et al.   MOLECULAR PHARMACEUTICS

Multiple myeloma

(2017) Shaji K. Kumar et al.   Nature Reviews Disease Primers

DNA repair of myeloma plasma cells correlates with clinical outcome: the effect of the nonhomologous end-joining inhibitor SCR7

(2016) M. Gkotzamanidou et al.   BLOOD

APRIL and BCMA promote human multiple myeloma growth and immunosuppression in the bone marrow microenvironment

(2016) Y.-T. Tai et al.   BLOOD

Evaluation of B cell maturation antigen as a target for antibody drug conjugate mediated cytotoxicity in multiple myeloma

(2016) Lydia Lee et al.   BRITISH JOURNAL OF HAEMATOLOGY

Gene Expression Profiles in Myeloma: Ready for the Real World?

(2016) Raphael Szalat et al.   CLINICAL CANCER RESEARCH

Update on elotuzumab, a novel anti-SLAMF7 monoclonal antibody for the treatment of multiple myeloma

(2016) Sagar Lonial et al.   EXPERT OPINION ON BIOLOGICAL THERAPY

A novel BCMA/CD3 bispecific T-cell engager for the treatment of multiple myeloma induces selective lysis in vitro and in vivo

(2016) S Hipp et al.   LEUKEMIA

ADCT-301, a Pyrrolobenzodiazepine (PBD) Dimer-Containing Antibody-Drug Conjugate (ADC) Targeting CD25-Expressing Hematological Malignancies

(2016) M. J. Flynn et al.   MOLECULAR CANCER THERAPEUTICS

Evidence for a role of the histone deacetylase SIRT6 in DNA damage response of multiple myeloma cells

(2015) Michele Cea et al.   BLOOD

Targeting B-cell maturation antigen in multiple myeloma

(2015) Yu-Tzu Tai et al.   Immunotherapy

SAR650984 directly induces multiple myeloma cell death via lysosomal-associated and apoptotic pathways, which is further enhanced by pomalidomide

(2015) H Jiang et al.   LEUKEMIA

Elotuzumab Therapy for Relapsed or Refractory Multiple Myeloma

(2015) Sagar Lonial et al.   NEW ENGLAND JOURNAL OF MEDICINE

Targeting CD38 with Daratumumab Monotherapy in Multiple Myeloma

(2015) Henk M. Lokhorst et al.   NEW ENGLAND JOURNAL OF MEDICINE

Synthetic Lethal Approaches Exploiting DNA Damage in Aggressive Myeloma

(2015) F. Cottini et al.   Cancer Discovery

Elotuzumab in combination with lenalidomide and dexamethasone in patients with relapsed multiple myeloma: final phase 2 results from the randomised, open-label, phase 1b–2 dose-escalation study

(2015) Paul G Richardson et al.   Lancet Haematology

Novel anti-B-cell maturation antigen antibody-drug conjugate (GSK2857916) selectively induces killing of multiple myeloma

(2014) Y.-T. Tai et al.   BLOOD

Rescue of Hippo coactivator YAP1 triggers DNA damage–induced apoptosis in hematological cancers

(2014) Francesca Cottini et al.   NATURE MEDICINE

Heterogeneity of genomic evolution and mutational profiles in multiple myeloma

(2014) Niccolo Bolli et al.   Nature Communications

Genomic instability in multiple myeloma: mechanisms and therapeutic implications

(2013) Paola Neri et al.   EXPERT OPINION ON BIOLOGICAL THERAPY

Intraclonal heterogeneity is a critical early event in the development of myeloma and precedes the development of clinical symptoms

(2013) B A Walker et al.   LEUKEMIA

CRM1 inhibition induces tumor cell cytotoxicity and impairs osteoclastogenesis in multiple myeloma: molecular mechanisms and therapeutic implications

(2013) Y-T Tai et al.   LEUKEMIA

Bruton tyrosine kinase inhibition is a novel therapeutic strategy targeting tumor in the bone marrow microenvironment in multiple myeloma

(2012) Y.-T. Tai et al.   BLOOD

Bortezomib-induced "BRCAness" sensitizes multiple myeloma cells to PARP inhibitors

(2011) P. Neri et al.   BLOOD

Evidence for ongoing DNA damage in multiple myeloma cells as revealed by constitutive phosphorylation of H2AX

(2011) D K Walters et al.   LEUKEMIA

Mechanism of RAD51-Dependent DNA Interstrand Cross-Link Repair

(2011) D. T. Long et al.   SCIENCE

Genome-Wide siRNA Screen for Modulators of Cell Death Induced by Proteasome Inhibitor Bortezomib

(2010) Siquan Chen et al.   CANCER RESEARCH

Drug Combination Studies and Their Synergy Quantification Using the Chou-Talalay Method

(2010) T.-C. Chou   CANCER RESEARCH

Daratumumab, a Novel Therapeutic Human CD38 Monoclonal Antibody, Induces Killing of Multiple Myeloma and Other Hematological Tumors

(2010) M. de Weers et al.   JOURNAL OF IMMUNOLOGY

Anti-CS1 humanized monoclonal antibody HuLuc63 inhibits myeloma cell adhesion and induces antibody-dependent cellular cytotoxicity in the bone marrow milieu

(2007) Y.-T. Tai et al.   BLOOD